This scenario suggests that the dynamics between IGF-1 LR3 and IGFBPs might be critical in determining the functional outcomes of IGF-1 LR3 in specific experimental contexts
12 Treatment with mecasermin may increase the risk of benign and malignant tumours, although the relationship between mecasermin and the risk of benign and malignant tumours is uncertain
It has not been evaluated or approved by the FDA, EMA, or any other regulatory authority for human or animal use
However, to promote significant muscle or bone growth, a higher dose may be warranted
The exposure of HaCaT cells to 0, 0.1, 0.25, 0.5, or 1 mg/mL GSH for 72 h resulted in the concentration-dependent induction of apoptosis (Figure 2b,c)